Scientific Posters , RapidFACT®

Utilization of RapidFACT® strategies to evaluate and develop an In Vitro - In Vivo Correlation (IVIVC) for Modified Release Formulations of Lorcaserin HCl

18 December 2025

Home
Resources
Utilization of RapidFACT® strategies to evaluate and develop an In Vitro - In Vivo Correlation (IVIVC) for Modified Release Formulations of Lorcaserin HCl

Overview

A RapidFACT® study was conducted to identify and optimize an MR formulation of lorcaserin. This presentation describes the clinical processes and data analyses involved in establishing an IVIVC for a series of prototype MR lorcaserin formulations.

The slowest release rate formulation was selected for further development.

Download

First name

Last name

Company name

Job title

Phone

City

Country

Do you want to opt into updates on news and info?

Yes, please opt me in for updates

No, I don't wish to receive updates

Date

18 December 2025

Translational Pharmaceutics® for integrated drug development

We can apply Translational Pharmaceutics® to your next drug program, whether your goal is getting to first-in-human trials faster, optimizing your drug product further coming out of Phase I studies, or for enabling more successful human ADME programs.

Translational Pharmaceutics® Contact Us

How does Translational Pharmaceutics work?

Utilization of RapidFACT® strategies to evaluate and develop an In Vitro - In Vivo Correlation (IVIVC) for Modified Release Formulations of Lorcaserin HCl

Download

Date

Share

Translational Pharmaceutics® for integrated drug development

Learn more about Translational Pharmaceutics®: